CVS Quote, Financials, Valuation and Earnings

Humana has a net margin of 0.09% compared to CVS Health's net margin of 1.63%. CVS Health's return on equity of 6.68% beat Humana's return on equity of 8.1%.

CVS Health has a consensus price target of $66.26, signalling upside risk potential of 49.74%. On the other hand Humana has an analysts' consensus of $287.90 which suggests that it could grow by 12.67%. Given that CVS Health has higher upside potential than Humana, analysts believe CVS Health is more attractive than Humana.

CVS Health has a beta of 0.541, which suggesting that the stock is 45.901% less volatile than S&P 500. In comparison Humana has a beta of 0.532, suggesting its less volatile than the S&P 500 by 46.758%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 6.01%. Humana offers a yield of 1.39% to investors and pays a quarterly dividend of $0.89 per share. CVS Health pays 37.54% of its earnings as a dividend. Humana pays out 17.32% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $95.4B, which are larger than Humana quarterly revenues of $29.4B. CVS Health's net income of $87M is lower than Humana's net income of $480M. Notably, CVS Health's price-to-earnings ratio is 11.23x while Humana's PE ratio is 22.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.15x versus 0.27x for Humana. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 0.09% compared to CVS Health's net margin of 8.48%. CVS Health's return on equity of 6.68% beat Eli Lilly and's return on equity of 66.4%.

CVS Health has a consensus price target of $66.26, signalling upside risk potential of 49.74%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 23.68%. Given that CVS Health has higher upside potential than Eli Lilly and, analysts believe CVS Health is more attractive than Eli Lilly and.

CVS Health has a beta of 0.541, which suggesting that the stock is 45.901% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 6.01%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.30 per share. CVS Health pays 37.54% of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $95.4B, which are larger than Eli Lilly and quarterly revenues of $11.4B. CVS Health's net income of $87M is lower than Eli Lilly and's net income of $970.3M. Notably, CVS Health's price-to-earnings ratio is 11.23x while Eli Lilly and's PE ratio is 86.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.15x versus 17.61x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Walgreens Boots Alliance has a net margin of 0.09% compared to CVS Health's net margin of 0.95%. CVS Health's return on equity of 6.68% beat Walgreens Boots Alliance's return on equity of -24.93%.

CVS Health has a consensus price target of $66.26, signalling upside risk potential of 49.74%. On the other hand Walgreens Boots Alliance has an analysts' consensus of -- which suggests that it could grow by 12.7%. Given that CVS Health has higher upside potential than Walgreens Boots Alliance, analysts believe CVS Health is more attractive than Walgreens Boots Alliance.

CVS Health has a beta of 0.541, which suggesting that the stock is 45.901% less volatile than S&P 500. In comparison Walgreens Boots Alliance has a beta of 0.664, suggesting its less volatile than the S&P 500 by 33.636%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 6.01%. Walgreens Boots Alliance offers a yield of 10.88% to investors and pays a quarterly dividend of $0.25 per share. CVS Health pays 37.54% of its earnings as a dividend. Walgreens Boots Alliance pays out -14.59% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $95.4B, which are larger than Walgreens Boots Alliance quarterly revenues of $36.4B. CVS Health's net income of $87M is lower than Walgreens Boots Alliance's net income of $344M. Notably, CVS Health's price-to-earnings ratio is 11.23x while Walgreens Boots Alliance's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.15x versus 0.05x for Walgreens Boots Alliance. Usually stocks with elevated PS ratios are considered overvalued.

SCWorx has a net margin of 0.09% compared to CVS Health's net margin of -55.94%. CVS Health's return on equity of 6.68% beat SCWorx's return on equity of -80.46%.

CVS Health has a consensus price target of $66.26, signalling upside risk potential of 49.74%. On the other hand SCWorx has an analysts' consensus of -- which suggests that it could fall by --. Given that CVS Health has higher upside potential than SCWorx, analysts believe CVS Health is more attractive than SCWorx.

CVS Health has a beta of 0.541, which suggesting that the stock is 45.901% less volatile than S&P 500. In comparison SCWorx has a beta of 2.792, suggesting its more volatile than the S&P 500 by 179.246%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 6.01%. SCWorx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CVS Health pays 37.54% of its earnings as a dividend. SCWorx pays out -- of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $95.4B, which are larger than SCWorx quarterly revenues of $759.7K. CVS Health's net income of $87M is higher than SCWorx's net income of -$425K. Notably, CVS Health's price-to-earnings ratio is 11.23x while SCWorx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.15x versus 0.65x for SCWorx. Usually stocks with elevated PS ratios are considered overvalued.